Pharmacogenetic Epidemiology of Birth Defects and Cancer

出生缺陷和癌症的药物遗传学流行病学

• 批准号: 6477759
• 负责人: LAURA E. MITCHELL
• 金额: $ 23.78万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-03-22 至 2005-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6477759
• 关键词: Internet; computer program /software; computer system design /evaluation; congenital disorders; disease /disorder etiology; disease /disorder proneness /risk; environment related neoplasm /cancer; environmental exposure; experimental designs; gene environment interaction; gene expression; genetic susceptibility; genome; microarray technology; molecular genetics; neoplasm /cancer epidemiology; pharmacogenetics; statistics /biometry

DESCRIPTION (provided by applicant): The current proposal is based on the premise that the genetic architecture of many common diseases will only be defined by a "genomic" approach that incorporates high throughput technologies and considers higher order effects (i.e., interactions involving multiple genes and/or environmental exposures). The proposed activities are motivated by the desires of the investigators to integrate their current molecular epidemiological approaches to the study of birth defects and cancer, and to expand their efforts to encompass a genomic approach to the study of pharmacological agents as risk factors for these conditions. These activities will build on methodological issues, pharmacological agents (e.g., folate antagonists) and genetic pathways (e.g., folate-homocysteine metabolic axis) that are common to birth defects and cancer. The successful expansion of research efforts to encompass a genomics approach will require expertise from multiple disciplines which traditionally have not been well integrated. Hence, funding for the proposed project will be used to establish, at the University of Pennsylvania School of Medicine (PENN), a research team that has the scientific expertise and technological resources required to undertake a genomic approach to the study of disease etiology. The tools and resources developed by this team will provide the foundation for future "genome-based" studies of pharmacological agents as risk factors for birth defects and cancer. In addition, since many of the tools and resources that are required of a genomic approach are neither disease- nor exposure- specific, the work of this team will also serve to foster, at PENN, genomic research on many additional environmentally-induced diseases.

描述（由申请人提供）： 当前的提议是基于以下前提 许多常见疾病只能通过一种“基因组”方法来定义 合并高通量技术并考虑高阶效应 （即，涉及多个基因和/或环境暴露的相互作用）。 提议的活动是由调查人员的愿望激励 将他们当前的分子流行病学方法整合到研究 出生缺陷和癌症，并扩大其涵盖基因组的努力 研究药理学剂作为这些风险因素的方法 状况。 这些活动将基于方法论问题 药理学剂（例如叶酸拮抗剂）和遗传途径（例如， 叶酸 - 摩囊苷代谢轴）是先天缺陷和 癌症。 成功扩展了涵盖基因组学方法的研究工作 传统上没有多个学科的专业知识 整合得很好。 因此，拟议项目的资金将用于 在宾夕法尼亚大学医学院（Penn）建立 具有科学专业知识和技术资源的研究团队 需要采用基因组方法来研究疾病病因。 该团队开发的工具和资源将为 未来的“基于基因组”的药理学剂作为风险因素 出生缺陷和癌症。 此外，由于许多工具和资源 基因组方法所必需的既不是疾病，也不是暴露 具体而言，该团队的工作还将在宾夕法尼亚 研究许多其他环境诱发的疾病。